About iTeos Therapeutics
iTeos Therapeutics is a company based in Cambridge (United States) founded in 2011 was acquired by Concentra Biosciences in July 2025. iTeos Therapeutics has raised $204.31 million across 9 funding rounds from investors including Pfizer, Janus Henderson Investors and RTW Investments. The company has 32 employees as of December 31, 2022. iTeos Therapeutics offers products and services including Belrestotug (EOS-448), EOS-984, and EOS-215. iTeos Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
- Headquarter Cambridge, United States
- Employees 32 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Iteos Therapeutics Inc
-
Annual Revenue
$35 M (USD)178as on Dec 31, 2024
-
Net Profit
-$134.41 M (USD)-19as on Dec 31, 2024
-
EBITDA
-$159.53 M (USD)-6as on Dec 31, 2024
-
Total Equity Funding
$204.31 M (USD)
in 9 rounds
-
Latest Funding Round
$125.36 M (USD), Series B
Apr 01, 2020
-
Investors
Pfizer
& 19 more
-
Employee Count
32
as on Dec 31, 2022
-
Acquired by
Concentra Biosciences
(Jul 21, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of iTeos Therapeutics
iTeos Therapeutics offers a comprehensive portfolio of products and services, including Belrestotug (EOS-448), EOS-984, and EOS-215.
Immunotherapy targeting immune checkpoints for cancer treatment.
Drug candidate enhancing anti-tumor immune responses in trials.
Under development for advanced malignancies in clinical studies.
People of iTeos Therapeutics
Unlock access to complete
Leadership Team
14 people
Scientific Team
4 people
Software Development Team
4 people
Operations Team
3 people
Product Management Team
3 people
Human Resources and Administration
2 people
Finance and Accounting
2 people
CMC Team
1 people
Unlock access to complete
Funding Insights of iTeos Therapeutics
iTeos Therapeutics has successfully raised a total of $204.31M across 9 strategic funding rounds. The most recent funding activity was a Series B round of $125.36 million completed in April 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in iTeos Therapeutics
iTeos Therapeutics has secured backing from 20 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, Janus Henderson Investors and RTW Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biotech startups are funded by this venture capital firm.
|
Locked | Locked | Locked | |
|
Life Sciences focused VC firm investing in the US
|
Locked | Locked | Locked | |
|
Multiple sectors are targeted for venture capital investments.
|
Locked | Locked | Locked |
Investor details for iTeos Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by iTeos Therapeutics
Investment portfolio details for iTeos Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - iTeos Therapeutics
Detailed financials for iTeos Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Iteos Therapeutics Comparisons
Peer comparison for iTeos Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of iTeos Therapeutics
iTeos Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
Detailed competitors of iTeos Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Iteos Therapeutics
Complete news archive for iTeos Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about iTeos Therapeutics
iTeos Therapeutics was founded in 2011.
iTeos Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
iTeos Therapeutics is a funded company, having raised a total of $204.31M across 9 funding rounds to date.
As of Dec 31, 2022, the latest employee count at iTeos Therapeutics is 32.
Annual revenue of iTeos Therapeutics is $35M as on Dec 31, 2024.
iTeos Therapeutics was founded in 2011 and is based in Cambridge, United States. Focus is placed on immuno-oncology within the biotechnology sector, where anti-cancer agents are developed to address immuno-metabolism and immunosuppressive cells in the tumor microenvironment. Operations center on advancing a pipeline that includes an Adenosine A2A receptor antagonist currently in early-phase clinical trials, along with a TIGIT immune checkpoint blocking antibody.
iTeos Therapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
iTeos Therapeutics offers Belrestotug (EOS-448), EOS-984, and EOS-215.
iTeos Therapeutics has 20 investors. Key investors include Pfizer, Janus Henderson Investors, RTW Investments, Bpifrance, and RA Capital.